icon
icon
Overview

Acute myeloid leukemia is a rapidly progressing cancer of the blood-forming cells in the bone marrow. It develops when immature myeloid cells acquire abnormal changes, multiply uncontrollably and interfere with the production of healthy red blood cells, white blood cells and platelets.

AML does not usually form a single tumour. Leukemia cells are generally present in the bone marrow and blood and may sometimes involve the spleen, liver, lymph nodes, skin, gums, central nervous system or other tissues.

AML includes several biologically distinct subtypes defined by cell appearance, chromosome changes, gene mutations and the clinical setting in which the disease developed. Accurate classification is important because the subtype can influence prognosis, treatment selection and the need for stem-cell transplantation.

At Apollo Cancer Centres, AML care is planned by a multidisciplinary team that may include hemato-oncologists, pediatric oncologists, stem-cell transplant specialists, pathologists, molecular-diagnostics specialists, infectious-disease physicians, critical-care teams and supportive-care professionals.

Risk Factors for Acute Myeloid Leukemia

Most people diagnosed with AML have no identifiable or preventable cause. Factors associated with an increased risk include:
Increasing Age

Increasing Age

AML can occur at any age but is most frequently diagnosed in older adults.
Previous Chemotherapy

Previous Chemotherapy

Certain chemotherapy medicines, particularly alkylating agents and topoisomerase II inhibitors, can increase the risk of therapy-related AML.
Previous Radiation Therapy

Previous Radiation Therapy

Radiation used to treat another cancer may increase the risk, particularly when combined with chemotherapy.
Previous Blood or Bone-Marrow Disorder

Previous Blood or Bone-Marrow Disorder

Myelodysplastic syndromes, myeloproliferative neoplasms and some other marrow conditions can progress to AML.
Inherited Cancer-Predisposition Syndromes

Inherited Cancer-Predisposition Syndromes

Down syndrome, Fanconi anemia, Li-Fraumeni syndrome, germline RUNX1-related disorders, GATA2 deficiency and other rare conditions may increase risk.
Smoking

Smoking

Tobacco smoke contains chemicals that can damage bone-marrow cells and is an established modifiable risk factor.
Benzene Exposure

Benzene Exposure

Long-term or substantial occupational exposure to benzene is associated with AML.
High-Level Ionising Radiation

High-Level Ionising Radiation

Significant radiation exposure may increase the risk of developing leukemia.
Family History or Germline Predisposition

Family History or Germline Predisposition

Most AML is not inherited, but some families carry genetic variants that increase susceptibility to myeloid cancers.
Clonal Hematopoiesis

Clonal Hematopoiesis

Age-related blood-cell clones carrying certain mutations can occasionally progress to AML or another myeloid cancer.
Having a risk factor does not mean that a person will develop AML. Many patients have none of these factors, and most people with one or more risk factors never develop the disease.

Acute Myeloid Leukemia Signs and Symptoms

AML symptoms often develop over several weeks as leukemia cells interfere with normal blood-cell production. Possible symptoms include:

Persistent tiredness or weakness

Pale skin

Breathlessness during usual activity

Dizziness or headaches

Frequent or persistent fever

Recurrent or severe infections

Easy bruising

Frequent nosebleeds or bleeding gums

Prolonged bleeding from minor injuries

Small red or purple spots beneath the skin

Heavy menstrual bleeding

Bone or joint pain

Abdominal fullness or discomfort

Enlargement of the liver or spleen

Swollen lymph nodes

Reduced appetite

Unexplained weight loss

Night sweats

Swollen, painful or bleeding gums

Raised or discoloured skin lesions

Headache, vomiting, visual changes or weakness when the central nervous system is involved

Breathing difficulty, confusion or visual disturbance associated with a very high white-cell count

Severe or uncontrolled bleeding

These symptoms may also occur with infections and non-cancerous conditions. Persistent symptoms accompanied by abnormal blood counts, unexplained bleeding or marked weakness require prompt assessment. Severe bleeding, breathing difficulty, confusion, visual disturbance or signs of serious infection require urgent medical care

How Acute Myeloid Leukemia Is Diagnosed

AML is usually suspected after a complete blood count or peripheral blood smear identifies abnormal blood-cell levels or circulating blast cells. A bone-marrow examination is generally required to confirm the diagnosis and obtain material for detailed immunophenotypic, chromosome and molecular testing.

Some recurrent genetic abnormalities can establish an AML diagnosis even when the blast percentage is below the threshold traditionally used for other subtypes. The results must also distinguish AML from acute lymphoblastic leukemia, mixed-phenotype acute leukemia, myelodysplastic syndromes and other myeloid disorders. Accurate classification should be completed promptly so that treatment can be selected according to the disease biology and the patient's clinical condition.

• •

Chest X-ray

A chest X-ray may be performed when the patient has fever, cough, breathlessness or suspected pneumonia. It can identify lung infection, fluid around the lungs or another cause of respiratory symptoms. A baseline chest X-ray may also be obtained before intensive treatment in selected patients. However, a normal X-ray does not exclude an early infection in someone with a weakened immune system. CT may be required when symptoms persist or more detailed assessment is needed.

CT Scan

CT may be used to investigate fever, abdominal pain, breathing difficulty, neurological symptoms or suspected internal bleeding. Chest CT can detect fungal or bacterial lung infection more sensitively than a routine X-ray. Abdominal and pelvic CT may assess the liver, spleen, lymph nodes, bowel or another source of infection. It can also evaluate a suspected myeloid sarcoma, which is a mass of leukemia cells outside the bone marrow. Intravenous contrast is used according to kidney function and the clinical question.

MRI

MRI provides detailed assessment of the brain, spine, nerves, soft tissues and bone marrow without ionising radiation. It may be performed for persistent headache, weakness, seizures, spinal symptoms or suspected central nervous system involvement. MRI can also evaluate an extramedullary mass or possible myeloid sarcoma. It does not replace cerebrospinal-fluid examination when microscopic central nervous system disease is suspected. The urgency of imaging depends on the patient's neurological condition and clinical stability.

Ultrasound

Ultrasound may evaluate an enlarged liver or spleen, abdominal symptoms, swollen lymph nodes or a suspected collection of fluid. It may also assess blood flow when a catheter-related clot is suspected. Ultrasound is portable and does not involve radiation, making it useful in acutely unwell patients. It is not routinely needed to diagnose AML. Suspicious findings may require further imaging or tissue sampling.

PET-CT Scan

PET-CT is not routinely used to diagnose or monitor typical bone-marrow AML. It may be considered when myeloid sarcoma or another extramedullary site is suspected. Increased tracer uptake can also occur with infection or inflammation and therefore requires careful interpretation. Bone-marrow examination and molecular or MRD testing remain more appropriate for assessing systemic response. PET-CT may occasionally help define the extent of an extramedullary lesion or select a biopsy site.

Echocardiogram

An echocardiogram assesses heart structure and function before treatment that may include an anthracycline medicine. It establishes a baseline and can help determine whether standard intensive chemotherapy is appropriate. An electrocardiogram may also be performed, particularly when medicines can affect heart rhythm. Pre-existing cardiac disease may influence drug selection, dose or monitoring. Cardiac assessment may be repeated if symptoms or treatment-related concerns develop.

Bone-Marrow Aspiration

Bone-marrow aspiration removes liquid marrow, usually from the back of the hip bone. The sample is examined to determine the percentage, appearance and characteristics of blast cells. It also provides cells for flow cytometry, chromosome analysis, fluorescence in-situ hybridisation and molecular testing. These studies establish the AML subtype and identify findings that may influence prognosis or targeted treatment. Repeat aspiration may be used to assess remission and measurable residual disease.

Bone-Marrow Biopsy

A bone-marrow biopsy removes a small core of bone and marrow, usually during the same procedure as aspiration. It shows marrow cellularity, architecture, fibrosis and the pattern of leukemia-cell infiltration. Biopsy is especially useful when aspiration produces insufficient material or a "dry tap." Immunohistochemistry can help confirm myeloid differentiation and identify specific cell populations. Temporary soreness or bruising may occur, while serious bleeding or infection is uncommon.

Lumbar Puncture

Lumbar puncture is not routinely required for every patient with AML because central nervous system involvement is uncommon. It may be performed when the patient has neurological symptoms, certain high-risk features or known extramedullary disease. Cerebrospinal fluid is collected from the lower back and examined for leukemia cells. Intrathecal chemotherapy may be administered during the procedure when central nervous system treatment is required. The timing considers the platelet count, bleeding risk and presence of circulating blasts.

Biopsy of an Extramedullary Mass

AML may occasionally form a tumour outside the bone marrow called myeloid sarcoma. A tissue biopsy may be needed when a mass is the first or predominant manifestation of disease. The specimen undergoes histology, immunohistochemistry and molecular testing to distinguish myeloid sarcoma from lymphoma or another cancer. Bone-marrow and blood evaluation remain necessary because apparently localised disease may be part of systemic AML. Treatment generally follows systemic AML principles.

Laboratory

Blood and bone-marrow samples undergo detailed morphological, immunophenotypic, cytogenetic and molecular assessment. Testing may include:

  • Complete blood count: Measures red blood cells, white blood cells and platelets and may show anemia, thrombocytopenia, neutropenia or an abnormal white-cell count.

  • Peripheral blood smear: Examines blood-cell appearance and may identify circulating myeloblasts or Auer rods.

  • Bone-marrow morphology: Determines the proportion and appearance of blasts and evaluates normal blood-cell production.

  • Cytochemistry: Selected stains may help demonstrate myeloid differentiation when required.

  • Flow cytometry: Identifies proteins expressed by abnormal cells and distinguishes AML from ALL, mixed-phenotype leukemia and other marrow disorders.

  • Chromosome analysis: Detects numerical or structural chromosome abnormalities that contribute to classification and risk assessment.

  • FISH testing: Rapidly identifies selected rearrangements or chromosome changes when an urgent or targeted result is needed.

  • FLT3 testing: Identifies FLT3 mutations that may make the patient eligible for FLT3-targeted treatment.

  • NPM1 testing: Helps define disease subtype and risk and may provide a molecular marker for response monitoring.

  • CEBPA testing: Identifies specific mutations associated with a distinct AML subtype and prognostic group.

  • IDH1 and IDH2 testing: May identify eligibility for an IDH inhibitor in appropriate clinical settings.

  • Coagulation testing: PT, aPTT, fibrinogen and D-dimer assess unexplained bleeding, abnormal clotting or treatment-related complications.

  • Tumour-lysis tests: Uric acid, potassium, phosphate, calcium, creatinine and LDH assess tumour-lysis risk and organ effects.

  • Infection screening: May include hepatitis B, hepatitis C, HIV and other tests before immunosuppressive therapy.

  • HLA typing: Assesses potential compatibility with related or unrelated stem-cell donors when transplantation may be required.

  • Germline genetic testing: May be recommended when age, family history or molecular findings suggest an inherited predisposition to myeloid cancer.

AML classification should integrate morphology, immunophenotype, genetic abnormalities and clinical history. Molecular results may affect diagnosis, prognostic grouping, treatment selection, transplant planning and the method used to monitor residual disease.

Staging of Acute Myeloid Leukemia

AML is not usually staged from I to IV because leukemia cells are present in the blood-forming system from the outset. Instead, patients are classified according to disease biology, genetic risk, previous disorders or treatment, and response to therapy.

Risk assessment may consider:

  • Age and general health

  • White-cell count and clinical condition at presentation

  • Whether AML developed after a previous blood disorder

  • Previous chemotherapy or radiation exposure

  • Chromosome abnormalities

  • Gene mutations and molecular subtype

  • Presence of extramedullary or central nervous system disease

  • Response to induction treatment

  • Measurable residual disease after treatment

  • Whether the disease is newly diagnosed, refractory or relapsed

  • Duration of the first remission

  • Suitability for intensive treatment or stem-cell transplantation

The European LeukemiaNet system classifies adult AML into favourable-, intermediate- and adverse-risk groups using chromosome and molecular findings. These categories help estimate relapse risk and guide decisions about consolidation and stem-cell transplantation.

Favourable-risk disease includes selected core-binding-factor leukemias and AML with certain NPM1 or CEBPA alterations. Adverse-risk disease includes particular chromosome abnormalities, TP53 alterations and defined myelodysplasia-related genetic changes. Findings not assigned to either category may fall into the intermediate-risk group.

Genetic risk is not interpreted in isolation. Age, general health, treatment received and MRD response can substantially affect prognosis. Risk may be reassessed when additional molecular results become available or if the disease returns.

Acute Myeloid Leukemia Acute Myeloid Leukemia

How Acute Myeloid Leukemia Is Treated

• •

Intensive Induction Therapy

Intensive induction aims to achieve complete remission by reducing leukemia cells and restoring normal blood-cell production. A commonly used approach combines cytarabine given over several days with an anthracycline medicine. Other medicines may be added according to the disease subtype, genetic findings and treatment protocol.

Patients with a suitable FLT3 mutation may receive a FLT3 inhibitor with induction therapy. Gemtuzumab ozogamicin, an antibody–drug conjugate targeting CD33, may be incorporated for selected patients, particularly those with favourable-risk core-binding-factor AML. Clinical trials may offer additional targeted or immune-based combinations.

Intensive induction causes profound temporary bone-marrow suppression. Patients require close monitoring for infection, bleeding, tumour lysis, organ toxicity and other complications. Bone-marrow assessment is performed at protocol-defined time points to determine response and plan further treatment.

Lower-Intensity Treatment

Older adults and patients with significant medical conditions may not be suitable for intensive induction. Lower-intensity treatment often combines a hypomethylating agent, such as azacitidine or decitabine, with venetoclax. Venetoclax targets BCL-2, a protein that helps leukemia cells survive.

These regimens can produce deep remissions but may still cause prolonged neutropenia, infection and low platelet counts. Treatment schedules and doses may require adjustment according to marrow response, blood-count recovery and interactions with antifungal medicines. Bone-marrow examinations help distinguish persistent leukemia from treatment-related marrow suppression.

Other options may include low-dose cytarabine, a hypomethylating agent alone or targeted therapy when an appropriate mutation is present. Selection considers the likelihood of benefit, treatment burden, quality of life and the patient's goals.

Consolidation Therapy

Consolidation is given after remission to eliminate residual leukemia cells and reduce the risk of relapse. Patients with favourable-risk disease may receive several cycles of high- or intermediate-dose cytarabine-based chemotherapy. The number and intensity of cycles depend on age, subtype, genetic findings and treatment tolerance.

Patients with intermediate- or adverse-risk disease may be considered for allogeneic stem-cell transplantation during the first remission. MRD results are increasingly used to refine this decision. Persistent MRD can indicate a higher relapse risk even when standard remission criteria have been met.

Consolidation can cause infection, bleeding, neurological effects, eye irritation and prolonged blood-count suppression. Patients are monitored closely between cycles, and treatment is delayed or adjusted when recovery is inadequate.

Targeted Treatment

Targeted medicines are selected according to mutations or proteins identified in the leukemia cells. FLT3 inhibitors may be used during frontline treatment, maintenance in selected settings or treatment of relapsed FLT3-mutated AML. The exact medicine and combination depend on disease status and the treatment protocol.

IDH1 or IDH2 inhibitors may be used for selected patients whose leukemia carries the corresponding mutation. These medicines may cause differentiation syndrome and require appropriate monitoring. Gemtuzumab ozogamicin targets CD33 and may be incorporated into treatment for eligible patients.

Targeted treatments are not interchangeable across all AML subtypes. Molecular testing at diagnosis and relapse is important because the genetic profile can change over time. Treatment selection also considers previous therapy, organ function, medicine interactions and transplant plans.

Maintenance Therapy

Maintenance treatment may be considered after remission and consolidation for selected patients who are not proceeding immediately to stem-cell transplantation. Oral azacitidine may be used in certain adults who achieved remission after intensive chemotherapy but cannot complete further intensive curative treatment.

Maintenance is intended to prolong remission rather than replace adequate induction and consolidation. It is given in repeated cycles and continued while it remains beneficial and tolerable. Blood counts and organ function are monitored, and doses may be adjusted for toxicity.

The suitability of maintenance depends on the previous treatment, disease risk, MRD findings, transplant plan and the patient's general health. Not every patient with AML requires maintenance therapy.

Treatment of Relapsed or Refractory AML

Refractory AML does not enter remission with initial treatment, while relapsed AML returns after remission. Repeat molecular testing is important because new targetable abnormalities may be identified. Treatment depends on the duration of the first remission, previous medicines, genetic findings, age, organ function and transplant eligibility.

Options may include salvage chemotherapy, venetoclax-based treatment, a FLT3 inhibitor, an IDH inhibitor, gemtuzumab ozogamicin or a clinical trial. The objective is often to achieve another remission and proceed to allogeneic stem-cell transplantation when appropriate. Some patients may receive lower-intensity disease control and supportive care based on their health and preferences.

Relapse after transplantation may be treated using targeted therapy, chemotherapy, reduced immunosuppression, donor lymphocyte infusion or another transplant-related strategy. Treatment is individualised because relapsed AML varies widely in biology and clinical behaviour.

Allogeneic Stem-Cell Transplantation

Allogeneic hematopoietic stem-cell transplantation replaces the patient's blood-forming system with stem cells from a compatible donor. It is commonly considered for eligible patients with intermediate- or adverse-risk AML, persistent MRD, primary refractory disease or AML that has relapsed and returned to remission.

Before transplantation, conditioning chemotherapy, with or without radiation, reduces leukemia and suppresses the immune system. Donor cells can produce a graft-versus-leukemia effect, in which the new immune system attacks residual cancer cells. Donors may be matched siblings, matched or mismatched unrelated individuals, haploidentical relatives or cord-blood sources.

Risks include severe infection, organ toxicity, infertility, graft failure, graft-versus-host disease and treatment-related mortality. The decision balances these risks against the probability of relapse without transplantation. Age, health, disease risk, MRD, donor availability and patient preferences are considered.

Autologous Stem-Cell Transplantation

Autologous transplantation uses the patient's own previously collected stem cells. It does not provide a graft-versus-leukemia effect and is much less commonly used in AML than allogeneic transplantation. It may be considered for a small, carefully selected group of patients when an allogeneic donor is unavailable or unsuitable.

The procedure requires the patient to be in a deep remission without detectable contamination of the collected cells. Relapse remains an important concern because the reinfused immune system does not attack leukemia in the same way as donor cells. Its role varies between treatment programmes and is not appropriate for most patients.

Radiation for Myeloid Sarcoma

Radiation may be used when a myeloid sarcoma causes pain, nerve compression, impaired organ function or another urgent local problem. It may also be considered when a local mass persists after systemic treatment. Radiation can reduce the mass and improve local control, but it does not replace systemic AML therapy.

The dose and treatment area depend on the site, size, symptoms and previous treatment. Nearby organs are protected as much as possible during planning. Surgery may occasionally be required to obtain tissue or relieve compression, but chemotherapy remains the principal treatment.

Central Nervous System Radiation

Central nervous system involvement is uncommon in AML. Treatment usually includes intrathecal chemotherapy and systemic therapy capable of treating leukemia throughout the body. Cranial or craniospinal radiation may be considered for persistent, recurrent or bulky disease in selected patients.

The decision considers age, neurological symptoms, previous treatment and potential long-term effects. Radiation is planned carefully to limit exposure to the brain, eyes, spinal cord and endocrine structures. It is not used routinely as preventive treatment for most patients with AML.

Total-Body Irradiation

Total-body irradiation may be incorporated into the conditioning regimen before allogeneic stem-cell transplantation. It treats leukemia cells throughout the body and suppresses the immune system before donor-cell infusion. Many AML transplants instead use chemotherapy-only conditioning.

The conditioning approach depends on age, organ function, disease status and transplant protocol. Potential effects include fatigue, mouth soreness, infertility, cataracts, endocrine problems and an increased risk of later cancers. Long-term follow-up is required after transplantation.

Palliative Radiation Therapy

Short-course radiation may relieve pain, bleeding, nerve compression or other symptoms caused by a localised leukemia deposit. It is generally used alongside systemic treatment or supportive care. The schedule is selected to provide symptom relief while limiting treatment burden.

Response may develop during treatment or over the following weeks. Pain medicines and other symptom-directed measures continue alongside radiation. Palliative radiation does not treat leukemia throughout the body.

Acute Myeloid Leukemia
Prognosis for Acute Myeloid Leukemia

AML can be cured in some patients, but outcomes vary considerably. Prognosis depends on the biological characteristics of the leukemia, patient health and depth of response to treatment rather than on anatomical stage.

Factors influencing prognosis include:
Age at diagnosis
General health and organ function
Chromosome and molecular findings
Whether AML developed after another blood disorder
Previous chemotherapy or radiation
White-cell count and clinical condition at presentation
Ability to receive intensive treatment
Response to induction therapy
MRD after treatment
Whether transplantation is appropriate
Whether the disease is newly diagnosed, refractory or relapsed
Duration of the first remission
Availability of targeted treatment
Response to salvage therapy

Follow-up includes clinical assessment, blood counts and bone-marrow examinations when indicated. Molecular monitoring may be used for subtypes with a suitable marker, such as NPM1-mutated AML. Survivorship care addresses heart health, infections, immunity, fertility, emotional well-being and late effects of chemotherapy or transplantation.

Why Choose ACC for Acute Myeloid Leukemia Treatment

Multidisciplinary care involving hemato-oncology, pediatric oncology, stem-cell transplantation, pathology, molecular diagnostics, infectious diseases, critical care and supportive care

Rapid blood and bone-marrow assessment with flow cytometry, cytogenetics, FISH and molecular profiling

Measurable residual disease monitoring using validated flow or molecular methods

Intensive and lower-intensity treatment selected according to age, health and disease biology

FLT3-, IDH- and CD33-directed treatment for eligible patients

Allogeneic stem-cell transplantation for selected high-risk, refractory or relapsed AML

Access to cellular therapy and clinical trials where appropriate

Dedicated blood-product, infection, tumour-lysis and critical-care support

Management of myeloid sarcoma and central nervous system disease

Fertility, nutrition, psychological, rehabilitation and palliative-care support

Structured follow-up and survivorship care
Frequently Asked Questions
01 Is AML the same as ALL?
icon icon
No. AML develops from abnormal myeloid precursor cells, while ALL develops from immature lymphoid cells. Flow cytometry and molecular testing distinguish the two because their treatments differ.
02 Does AML develop quickly?
icon icon
Yes. AML is an acute leukemia and can progress over days or weeks. Prompt evaluation and treatment planning are important, particularly when there is infection, bleeding or a very high white-cell count.
03 Is AML inherited?
icon icon
Most AML is not inherited. However, rare germline genetic variants can increase susceptibility, particularly in younger patients or families with several blood cancers or unexplained low blood counts.
04 Why is a bone-marrow test necessary?
icon icon
A bone-marrow examination confirms the disease, evaluates blast cells and provides material for flow cytometry, chromosome analysis and molecular testing. It is also used to assess remission and MRD.
05 Why is molecular testing important in AML?
icon icon
Molecular testing identifies genetic changes that help classify AML, estimate relapse risk and select targeted treatment. The results may also influence stem-cell transplant decisions and determine how treatment response is monitored.
06 Does every patient receive intensive chemotherapy?
icon icon
No. Treatment intensity depends on age, health, organ function, AML biology and patient preferences. Lower-intensity combinations can be effective for patients who are not candidates for intensive induction.
07 What is measurable residual disease?
icon icon
MRD refers to leukemia cells that remain after treatment but cannot be detected by routine microscopy. Flow cytometry or molecular tests can identify these cells and help estimate relapse risk.
08 Does remission mean that AML is cured?
icon icon
Not necessarily. Remission means that leukemia is no longer detectable by standard criteria and normal blood-cell production has recovered. Consolidation or transplantation may still be required to reduce relapse risk.
09 Does every patient need a stem-cell transplant?
icon icon
No. Transplantation is considered according to genetic risk, MRD response, relapse risk, age, health and donor availability. Many patients with favourable-risk AML are treated without a transplant during first remission.
10 Is CAR T-cell therapy available for AML?
icon icon
CAR T-cell therapy is not currently a standard treatment for AML. Several cellular approaches are being studied in clinical trials, but identifying a safe and effective target remains challenging.
11 Can AML return after treatment?
icon icon
Yes. AML may relapse in the bone marrow, blood or an extramedullary site. Treatment may include salvage chemotherapy, targeted medicines, transplantation or a clinical trial.
12 Can patients return to normal activities after treatment?
icon icon
Many patients resume usual activities after recovery, although the timing varies. Blood-count recovery, infection risk, fatigue and transplant-related effects may require gradual rehabilitation and long-term follow-up.
image image
Book an Appointment
Please Enter Your Name
Please Enter Your Mobile Number
Please Enter OTP